Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It … Read more
Lincoln Pharmaceuticals Limited (LINCOLN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.070x
Based on the latest financial reports, Lincoln Pharmaceuticals Limited (LINCOLN) has a cash flow conversion efficiency ratio of 0.070x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹497.63 Million) by net assets (₹7.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lincoln Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Lincoln Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lincoln Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lincoln Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIOINVENT INTERN. SK 2
F:BIX0
|
N/A |
|
High Tech Pharm Co. Ltd
KQ:106190
|
0.052x |
|
NNIT A/S
LSE:0R5Z
|
0.044x |
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
0.112x |
|
Cox Energy América, S.A.B. de C.V.
MC:COXE
|
0.175x |
|
Wieson Technologies Co Ltd
TWO:6272
|
0.046x |
|
UBcare. Co. Ltd
KQ:032620
|
0.057x |
|
Cabral Gold Inc
PINK:CBGZF
|
-0.359x |
Annual Cash Flow Conversion Efficiency for Lincoln Pharmaceuticals Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Lincoln Pharmaceuticals Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹6.72 Billion | ₹930.15 Million | 0.138x | +29.87% |
| 2024-03-31 | ₹5.93 Billion | ₹632.17 Million | 0.107x | +36.47% |
| 2023-03-31 | ₹5.02 Billion | ₹392.62 Million | 0.078x | -55.57% |
| 2022-03-31 | ₹4.33 Billion | ₹761.32 Million | 0.176x | -6.97% |
| 2021-03-31 | ₹3.66 Billion | ₹692.70 Million | 0.189x | -21.42% |
| 2020-03-31 | ₹3.13 Billion | ₹754.15 Million | 0.241x | +22.78% |
| 2019-03-31 | ₹2.70 Billion | ₹528.45 Million | 0.196x | +90.07% |
| 2018-03-31 | ₹2.25 Billion | ₹231.48 Million | 0.103x | -20.68% |
| 2017-03-31 | ₹1.93 Billion | ₹250.41 Million | 0.130x | -58.91% |
| 2016-03-31 | ₹1.42 Billion | ₹447.99 Million | 0.316x | +47.11% |
| 2015-03-31 | ₹1.14 Billion | ₹245.59 Million | 0.215x | +375.15% |
| 2014-03-31 | ₹1.03 Billion | ₹46.38 Million | 0.045x | +127.11% |
| 2013-03-31 | ₹934.78 Million | ₹-155.99 Million | -0.167x | -219.64% |
| 2012-03-31 | ₹850.86 Million | ₹118.67 Million | 0.139x | +148.97% |
| 2011-03-31 | ₹722.92 Million | ₹-205.89 Million | -0.285x | -43.92% |
| 2010-03-31 | ₹532.87 Million | ₹-105.45 Million | -0.198x | -571.96% |
| 2009-03-31 | ₹364.41 Million | ₹15.28 Million | 0.042x | -86.83% |
| 2008-03-31 | ₹321.55 Million | ₹102.38 Million | 0.318x | +353.34% |
| 2007-03-31 | ₹285.77 Million | ₹20.07 Million | 0.070x | +182.94% |
| 2006-03-31 | ₹266.38 Million | ₹-22.56 Million | -0.085x | -- |